Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
- MVP-S treatment increased survivin-specific T and B cell tumor infiltration, further validating the MVP-S mechanism of action
- Immunogenic/inflamed tumors are more susceptible to treatment with MVP-S
- Potential mechanisms of primary resistance to treatment were identified
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving patients’ quality of life, today announced that translational data from the Phase 2 clinical study in patients with advanced, recurrent ovarian cancer will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
“Treatment with MVP-S elicited an immune response involving both survivin-specific T and B cells, which further extends our understanding of the MVP-S mechanism of action,” said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc. “These results help to bolster further confidence in the therapeutic mechanism of MVP-S based treatment and set the stage for the design of the next Phase 2B study in advanced, recurrent ovarian cancer patients, expected to begin next year.”
Twenty-two women with advanced, recurrent ovarian cancer were enrolled in the DeCidE1 study. Translational analyses showed that:
- A higher baseline CD3+CD8+ T cell infiltration in tumor tissue was evident in patients with clinical benefit (defined as >10% on-treatment tumor regression)
- Likewise, B cell pathway genes were significantly upregulated in patients with clinical benefit
- MVP-S treatment induced increased T and B cell infiltration into tumor on-treatment when compared to the pre-treatment tumor biopsy sample taken from a patient with defined clinical response by RECISTv1.1.
- Upregulation of genes or pathways related to immune-suppression (e.g. WNT pathway) or immune evasion/exclusion (CD276, Arg2) were significantly associated with lack of anti-tumor activity, suggesting a potential mechanism for treatment failure.
These findings suggest that immunogenic tumors are more susceptible to MVP-S treatment, in line with its mechanism of action. Collectively, these results provide insight for possible predictors of response to treatment with MVP-S. These translational data will inform the design of next IMV-sponsored clinical trial in patients with advanced, recurrent ovarian cancer, expected to be initiated in 2022. The study will evaluate MVP-S with intermittent low dose cyclophosphamide (CPA).
The poster will be presented on November 12, 2021, by Oliver Dorigo, M.D., Ph.D., Director and Associate Professor, Division Gynecologic Oncology, Department of Obstetrics and Gynecology at the Stanford University, CA.
- PosterTitle: Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
- Poster Number: 353
- Dr. Dorigo will be present in person at lunch time (12:40–2:10 p.m. EST) and during the poster reception (7–8:30 p.m. EST)
- An e-poster presentation will be available under the Scientific Publications & Posterssection on IMV’s website.